A
Alcista
Alcista · 25%MBX
$15.58
Precio del escenario
$50.290
+1.856 (+3.69%)Al cierre
Loading chart…
- Máximo
- 50.810
- Apertura
- 48.930
- Precio medio ponderado por volumen
- 49.68
- Volumen
- 653.05K
- Capitalización
- —
- Mínimo
- 47.930
- Importe
- 32.44M
- EV/EBITDA, TTM
- 0.00
MBX Biosciences, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders. It is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets and proven endpoints for regulatory approval. Its pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase III development and an obesity portfolio that includes MBX 4291 in Phase I development and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. Its lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent glucagon-like peptide 1 (GLP-1) / glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug with the goal of potential once-monthly dosing frequency.
Análisis de IA of MBX Biosciences Inc (MBX)
MantenerGiven the current price of $48.50 and a significant upside potential indicated by analyst price targets (up to $150), MBX Biosciences could be an attractive long-term investment. However, the RSI of 31.127 suggests the stock is oversold, indicating a potential for recovery. The main risk is the declining financial performance, with a net loss of $37.1 million in Q2 2026, which could affect investor confidence.
Métricas de valoración
El PER previsto actual de MBX Biosciences Inc (MBX) es 0.00, frente a su media de 5 años de -5.80.
Escenarios de precio de Alphio AI para MBX
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con MBX en cartera
Cronología de eventos
Noticias
9.508-06seekingalphaMBX Biosciences Reports Q2 2026 Financial Results
5.007-15GlobenewswireAttovia Appoints New Independent Director
5.007-15NewsfilterAttovia Appoints New Independent Director
2.007-14CNBCAnalysis of Major Stock Movements
- 9.006-12seekingalpha
MBX Biosciences Shares Drop After Trial Results Fall Short
Preguntas frecuentes sobre MBX, respondidas por Alphio AI
MBX Biosciences, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders. It is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets and proven endpoints for regulatory approval. Its pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase III development and an obesity portfolio that includes MBX 4291 in Phase I development and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. Its lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent glucagon-like peptide 1 (GLP-1) / glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug with the goal of potential once-monthly dosing frequency. It operates in the Healthcare sector.
Given the current price of $48.50 and a significant upside potential indicated by analyst price targets (up to $150), MBX Biosciences could be an attractive long-term investment. However, the RSI of 31.127 suggests the stock is oversold, indicating a potential for recovery. The main risk is the declining financial performance, with a net loss of $37.1 million in Q2 2026, which could affect investor confidence.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.